ES2171923T3 - Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. - Google Patents

Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.

Info

Publication number
ES2171923T3
ES2171923T3 ES97916380T ES97916380T ES2171923T3 ES 2171923 T3 ES2171923 T3 ES 2171923T3 ES 97916380 T ES97916380 T ES 97916380T ES 97916380 T ES97916380 T ES 97916380T ES 2171923 T3 ES2171923 T3 ES 2171923T3
Authority
ES
Spain
Prior art keywords
talidomide
medicines
profarms
preparation procedure
active principles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916380T
Other languages
English (en)
Inventor
Johannes Schneider
Werner Winter
Stephan Wnendt
Kai Zwingenberger
Kurt Eger
Michaela Akermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2171923T3 publication Critical patent/ES2171923T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE DESCRIBEN PRECURSORES DE TALIDOMIDA DE FORMULA (I), PROCEDIMIENTO PARA SU PREPARACION Y SU UTILIZACION COMO PRINCIPIO ACTIVO DE MEDICAMENTOS, EN LA CUAL R SIGNIFICA - CHR1 NHR2 O - (CH2)) N COOH, R1 ES H O ALQUILO DE C1-4 , R2 ES H, ALQUILO DE C1-3 , C(O) - CH2 NHR3 O UN GRUPO PROTECTOR DE AMINO, R3 ES H O UN GRUPO PROTECTOR DE AMINO Y N ES UN NUMERO ENTERO ENTRE 2 Y 4, EN FORMA DE SUS BASES O SALES DE ACIDOS FISIOLOGICOS.
ES97916380T 1996-04-09 1997-03-22 Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. Expired - Lifetime ES2171923T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Publications (1)

Publication Number Publication Date
ES2171923T3 true ES2171923T3 (es) 2002-09-16

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916380T Expired - Lifetime ES2171923T3 (es) 1996-04-09 1997-03-22 Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.

Country Status (13)

Country Link
US (1) US6417197B1 (es)
EP (1) EP0892794B1 (es)
JP (1) JP2000508298A (es)
CN (1) CN1102931C (es)
AT (1) ATE212989T1 (es)
AU (1) AU707144B2 (es)
DE (2) DE19613976C1 (es)
DK (1) DK0892794T3 (es)
ES (1) ES2171923T3 (es)
HK (1) HK1017350A1 (es)
HU (1) HUP9902181A3 (es)
PT (1) PT892794E (es)
WO (1) WO1997037988A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
WO1997045117A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
PT1308444E (pt) * 1997-11-18 2006-08-31 Celgene Corp 2-( 2,6-dioxo-3-fluoropiperidina-3-il )- isoindolinas e a sua utilizacao para reduzir os niveis de tnf
US20010041716A1 (en) * 1999-12-02 2001-11-15 Laing Timothy J. Compositions and methods for locally treating inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
CA2538864C (en) * 2003-09-17 2013-05-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
PL1682126T3 (pl) * 2003-10-16 2009-12-31 Novartis Vaccines & Diagnostics Inc Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2004614B1 (en) 2006-04-13 2016-10-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
PT2358697E (pt) * 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
TWI782395B (zh) * 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
US20200199097A1 (en) * 2017-08-21 2020-06-25 Nanjing Noratech Pharmaceuticals Co., Ltd Pomalidomide derivative and preparation method therefor
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
JP3204972B2 (ja) * 1991-04-17 2001-09-04 グリューネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規サリドマイド誘導体、その製造方法並びにこれを薬剤として使用する方法
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
HK1017350A1 (en) 1999-11-19
PT892794E (pt) 2002-07-31
EP0892794B1 (de) 2002-02-06
US6417197B1 (en) 2002-07-09
DE59706313D1 (de) 2002-03-21
DE19613976C1 (de) 1997-11-20
HUP9902181A2 (hu) 2000-04-28
JP2000508298A (ja) 2000-07-04
AU707144B2 (en) 1999-07-01
DK0892794T3 (da) 2002-04-15
WO1997037988A1 (de) 1997-10-16
EP0892794A1 (de) 1999-01-27
CN1215397A (zh) 1999-04-28
AU2505297A (en) 1997-10-29
HUP9902181A3 (en) 2002-11-28
ATE212989T1 (de) 2002-02-15
CN1102931C (zh) 2003-03-12

Similar Documents

Publication Publication Date Title
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
DK1165570T3 (da) Nye phosphorholdige prodrugs
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
MX9203653A (es) Composiciones amfotericas y formas polimericas de los alfa-hidroxiacidos.
ATE124405T1 (de) 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel.
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
BG102764A (en) Derivatives of pyrimidin-4-on as pesticides
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
HRP20010615B1 (en) Pharmaceutical compositions containing proton pump inhibitors
ES2061546T3 (es) Compuestos quelantes de piridoxamina, quelatos de manganeso (ii) y su uso como agentes de contraste de nmri.
BR0012429A (pt) Fórmulações para il-11
DE60317039D1 (de) Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
ATE206116T1 (de) 6-carboxamido-dihydropyran-derivate
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
AR012723A1 (es) Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos
FI945510A0 (fi) Klavulaanihapon diamiinisuolat
ES2054089T3 (es) Formulaciones orales liquidas.
ES2081144T3 (es) Amidas de aminoacidos substituidas.
AR028823A1 (es) 8a y 9a lactamas de 15 miembros de la clase 6-o-metil-eritromicina a, un procedimiento para su preparacion y una composicion farmaceutica util para el tratamiento de infecciones bacterianas en seres humanos y animales
FR2653303B1 (fr) Agents edulcorants de grande stabilite derivant des acides l-aspartique et l-glutamique n-hydrocarbones 1-oxo-2-ramifies.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 892794

Country of ref document: ES